New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management

(2015) Ayalew Tefferi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

(2015) Alessandro M. Vannucchi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia

(2014) G. Finazzi et al.   BLOOD

In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology

(2014) T. Barbui et al.   BLOOD

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

(2013) G. Rotunno et al.   BLOOD

Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target

(2012) S. Pascale et al.   BLOOD

Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)

(2012) T. Barbui et al.   BLOOD

Aspirin for Preventing the Recurrence of Venous Thromboembolism

(2012) Cecilia Becattini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Events and Intensity of Treatment in Polycythemia Vera

(2012) Roberto Marchioli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients

(2011) A. Carobbio et al.   BLOOD

Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980

(2011) Jean-Jacques Kiladjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocytemia

(2011) Jean-Guillaume Dillinger et al.   THROMBOSIS RESEARCH

Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia

(2010) A. Alvarez-Larran et al.   BLOOD

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

(2008) V. De Stefano et al.   HAEMATOLOGICA